Corrigendum to: Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression (Clinical and Experimental Immunology, (1998), 111, 1, (211-218), 10.1046/j.1365-2249.1998.00460.x);Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-α) and/or interferon-gamma (IFN-γ), resulting from down- modulation of Bcl-2 expression

Clinical and Experimental Immunology

Volumn 111, Issue 1, 1998, Pages 211-218

  Koshiji, M ^a   Adachi, Y ^a   Sogo, S ^b   Taketani, S ^a   Oyaizu, N ^c   Than, Soe ^d   Inaba, M ^a   Phawa, S ^d   Hioki, K ^a   Ikehara, S ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Bax; Bcl 2; COLO 201; Interferon gamma; Tumour necrosis factor alpha

Indexed keywords

DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 15444353992     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.13383     Document Type: Erratum

References (38)

1. Ito N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-43.
2. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747-56.
3. Montel AH, Bochan MR, Goebel WS, Brahmi Z. Fas-mediated cytotoxicity remains in perform and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol 1995; 165:312-7.
4. Tsujimoto Y, Croce CM. Analysis of structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83:5214-8.
5. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an innermitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348:334-6.
6. Chen-Levy Z, Nouese J, Cleary ML. The bcl-2 candidate protooncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 1989; 9:701-10.
7. McDonnell TJ, Denne N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57:79-88.
8. Lacronique V, Mignon A, Fabre M et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Med 1996; 2:80-86.
9. Johnson EM Jr, Deckwerth TL. Molecular mechanisms of developmental neuronal death. Annu Rev Neurosci 1993; 16:31-46.
10. Broome HE, Dargan CM, Bessent EF, Krajewski S, Reed JC, Apoptosis and Bcl-2 expression in cultured murine splenic T cells. Immunology 1995; 84:375-82.
11. Deng G, Podack ER. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA 1993; 90:2189-93.
12. Straser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67:889-99.
13. Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto V, Nowell PC, Greene MI, Reed JC. Differential effects of Bcl-2 on T cell and B cells in transgenic mice. Proc Natl Acad Sci USA 1992; 89:11376-80.
14. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75:229-40.
15. Nakayama KI, Nakayama K, Negishi I et al. Disappearance of the lymphoid system in bcl-2 homozygous mutant chimeric mice. Science 1993; 261:1584-8.
16. Oyaizu N, Thomas WM, Than S, Hu R, Kalyanaraman VS, Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing Interferon-γ and tumor necrosis factor-α secretion. Blood 1994; 84:2622-31.
17. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, Krammer PH. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994; 57:371-7.
18. Oltvai Z, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-19.
19. Yin X-M, Olitvai ZN, Korsmeyer SJ, BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369:321-3.
20. Semple TU, Quinn LA, Woods LK, Moore GE. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for cytotoxicity model. Cancer Res 1978; 38:1345-55.
21. O'Connell J, O'Sullivan CO, Collins JK, Shanaha F. The Fas counter-attack: Fas-mediated T cell killing by colon cancer expression Fas ligand. J Exp Med 1996; 184:1075-82.
22. L in the control of apoptosis in the murine melanoma cells. Cancer Res 1996; 56:1451-6.
23. Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JT. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989; 337:181-4.
24. Adachi Y, Oyaizu N, Than S, McCloskey TW, Pahwa S. IL-2 rescues in vivo lymphocyte apoptosis in patients with HIV infection. Correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 1996; 157:4184-93.
25. Nicoletti I, Migliorati G, Pagliacci MC, Riccardi C. A rapid simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
26. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood 1994; 84:2622-31.
27. Oyaizu N, Than S, McCloskey TW, Pahwa S. Requirement of p56lck in T-cell receptor/CD3-mediated apoptosis and Fas-ligand induction in Jurkat cells. BBRC 1995; 213:994-1001.
28. Trauth BC, Klas C, Peter AM, Matzuki S, Maller P, Falk W, Debatin KM, Krummer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301-4.
29. Suda T, Takuhashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
30. Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181:71-77.
31. Mapara MY, Bargou R, Zugck C, Dohner H, Ustaoglu F, Jonker RR, Krammer PH, Dorken B. Apo-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 1993; 23:702-8.
32. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995; 181:2029-46.
33. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151:621-7.
34. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon Alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995; 13:1110-22.
35. Kim CJ, Taubenherger JK, Simonis TB, White DE, Rosenberg SA. Marincola FM. Combination therapy with interferon-gamma and interleukin-2 for treatment of metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996; 19:50-58.
36. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154:41-42.
37. Sciller JH, Witt PL, Storer B et al. Clinical and biologic effect of combination therapy with gamma-interferon and tumor necrosis factor. Cancer 1992; 69:562-71.
38. + T cell function. Jpn J Cancer Res 1993; 84:315-25.